Ligand Pharmaceuticals Overview
Ligand Pharmaceuticals (LGND) has a P/E ratio of 28.32, above the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow28.32
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Ligand Pharmaceuticals (LGND) currently reports a P/E ratio of 28.32. That is above the Healthcare sector average of 25.3. Use the charts on this page to explore Ligand Pharmaceuticals's P/E ratio history and peer comparisons.
Ligand Pharmaceuticals's P/E ratio of 28.32 is higher than the Healthcare sector average of 25.3. That is roughly 12.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Ligand Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 28.32, LGND can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 28.32, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Ligand Pharmaceuticals, and consider following LGND for alerts when major investors trade the stock.
Ligand Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows 28.32 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LGND with unrelated industries.
